Ionis Pharmaceuticals (MIL:1IONS) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1IONS Ionis Pharmaceuticals Inc MIL:1IONS
48 GF Score
Price €48.44
GF Value €44.73
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

MIL:1IONS vs KYMR, PRAX, HALO: Short Interest Comparison

For the Biotechnology subindustry, Ionis Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ionis Pharmaceuticals Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Ionis Pharmaceuticals's Short Interest falls into.


MIL:1IONS
48GF Score
Ionis Pharmaceuticals Inc MIL:1IONS
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ionis Pharmaceuticals (MIL:1IONS) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of €48.44 is trading 8.3% above its estimated GF Value™ of €44.73. GuruFocus considers Ionis Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for MIL:1IONS:

  • Short Interest:
  • GF Value™: €44.73 vs. price of €48.44 (8.3% above fair value)
  • GF Score™: 48/100 with 5 warning signs

No single metric tells the full story. See the MIL:1IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ionis Pharmaceuticals Business Description

Other Exchanges IONS:USA0JDI:UKISI:Germany
Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
48GF Score

Get the complete analysis for MIL:1IONS

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€48.44
Price
€44.73
GF Value